In summary, our investigation supports a role for BRCA2 and HOXB13 mutations in prostate cancer predisposition and provides reassurance that BRCA1, RNASEL, and ELAC2 are not substantially contributory in this cohort. Here, ELAC2 is linked to prostate carcinoma.